Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for any mention of deals, orders, contracts, projects, customers, sites, programs getting bigger over time. Scan the transcript. There is mention of a large affinity market sale in Canada: "APE sales growth of 51% compared with the prior-year quarter, driven by a large affinity market sale" and later "this was our largest affinity sale ever, was the Ontario Medical Association. 36,000 new customers, $150 million to $160 million of premium." But is this presented as part of an upward drift? The context: "APE sales increased 51% compared with the prior-year quarter, primarily due to a large affinity market sale, which was the main contributor to our significant growth in new business value." It seems like a single exceptional event. No mention of progressive increase in size of affinity sales over time. Also, the question asks about "successive engagements of the same kind" coming in at progressively larger size. Here it's one large sale, not a pattern. Management does not frame it as part of an upward drift. They just say it was the largest ever, but that could be an isolated event. No indication that future ones will be larger. So answer NO. Also check other parts: No mention of increasing deal sizes elsewhere. So NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.